Literature DB >> 28166601

Mechanisms of Cellular Activation in the Antiphospholipid Syndrome.

Nadine Müller-Calleja1,2, Karl J Lackner1.   

Abstract

It is long known that antiphospholipid antibodies (aPL) induce proinflammatory and procoagulant cellular responses. The underlying signal transduction has been a major focus of research and is the topic of this review. An amazingly heterogeneous panel of signaling pathways has been described and it turns out that at least some of this heterogeneity can be explained by effects of distinct aPL species. On the one hand, there are antibodies against β2-glycoprotein I (β2GPI) which appear to exert their cellular effects only as a complex of β2GPI/anti-β2GPI. Their major targets are low-density lipoprotein-receptor related protein 8 (LRP8), annexin A2 (ANXA2), toll-like receptor 4 (TLR4), and possibly TLR2. The other relevant aPL species are antibodies against cardiolipin which are internalized into endosomes and induce cellular responses via activation of endosomal NADPH-oxidase. Their cell surface target is still unknown. Another important issue relates to the role of complement. It has been shown in vivo that certain pathogenic effects of aPL depend on complement activation, but the exact interplay with the signaling pathways described earlier needs to be elucidated. Thus, while there has been tremendous progress over the past decade, many open questions remain to be answered. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2017        PMID: 28166601     DOI: 10.1055/s-0036-1597290

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  8 in total

1.  Induction of tissue factor expression by anti-β2-glycoprotein I is mediated by tumor necrosis factor α.

Authors:  Anne Hollerbach; Nadine Müller-Calleja; Antje Canisius; Carolin Orning; Karl J Lackner
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

Review 2.  Antiphospholipid syndrome: an update for clinicians and scientists.

Authors:  Andrew P Vreede; Paula L Bockenstedt; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2017-09       Impact factor: 5.006

Review 3.  Pediatric antiphospholipid syndrome.

Authors:  Jacqueline A Madison; Yu Zuo; Jason S Knight
Journal:  Eur J Rheumatol       Date:  2019-12-03

Review 4.  Redox Activation of Mitochondrial DAMPs and the Metabolic Consequences for Development of Autoimmunity.

Authors:  Andreas Koenig; Iwona A Buskiewicz-Koenig
Journal:  Antioxid Redox Signal       Date:  2022-03       Impact factor: 7.468

5.  Anticardiolipin (aCL) in sera from periodontitis subjects activate Toll-like receptor 4 (TLR4).

Authors:  Harvey A Schenkein; Ravindar R Thomas
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

Review 6.  Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS".

Authors:  Roberta Misasi; Agostina Longo; Serena Recalchi; Daniela Caissutti; Gloria Riitano; Valeria Manganelli; Tina Garofalo; Maurizio Sorice; Antonella Capozzi
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

Review 7.  Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects.

Authors:  Aline Garcia Islabão; Vitor Cavalcanti Trindade; Licia Maria Henrique da Mota; Danieli Castro Oliveira Andrade; Clovis Artur Silva
Journal:  Paediatr Drugs       Date:  2021-12-13       Impact factor: 3.022

Review 8.  Antiphospholipid Antibodies and Lipids in Hematological Malignancies.

Authors:  Sonia Guadalupe Barreno-Rocha; Sandra Guzmán-Silahua; Sinaí-Del-Carmen Rodríguez-Dávila; Guadalupe Estela Gavilanez-Chávez; Ernesto Germán Cardona-Muñoz; Carlos Riebeling-Navarro; Benjamín Rubio-Jurado; Arnulfo Hernán Nava-Zavala
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.